AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03117127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Whole Eggs
Description: Participants will ingestion whole eggs immediately after resistance exercise
Study NCT03117127 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Egg Whites
Description: Participants will ingestion whole eggs immediately after resistance exercise
Study NCT02214082 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Same Day Discharge
Description: This group will be discharged home, on the same day after their elective angioplasty
Study NCT01237730 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cefuroxime
Description: Use the cefuroxime as prophylaxis.
Study NCT01237730 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tailored antibiotic
Description: Select the prophylactic antibiotics according to the patients oropharyngeal microorganism.
Study NCT03168724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: GMT intervention
Study NCT04136132 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biological collection
Description: The biological collection will also include samples of blood samples collected before or after surgery but also samples frozen and/or paraffin-embedded tissue sections.
Study NCT03588520 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Home Blood Pressure Monitoring
Description: Patients randomly assigned to the HBP-guided management group will perform home BP monitoring for 7 days with the use of a validated self-inflating automatic oscillometric device (HEM 705 CP, Omron Healthcare). Home BP monitoring will be performed according to the currently available European Society of Hypertension guidelines at the baseline visit and will be repeated 1 week before the prespecified follow-up visits (at Month 1, Month 2 and Month 4). Patients randomly assigned to the control group will receive conventional management of hypertension based on office BP recordings obtained with the same BP monitor (HEM 705 CP, Omron Healthcare) during the same prespecified follow-up visits.
Study NCT03877809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sirolimus 0.5 mg
Description: Daily administration of 1 or more tablets
Study NCT01141309 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sorafenib with everolimus
Description: Treatment will be with sorafenib 400 mg orally twice a day and everolimus 5 mg orally daily. Restage every 2 cycles \*Cycle = 4 weeks of treatment.~Subjects may consent to allowing blood to be drawn for DNA. Two blue top tubes will be required. Approximately 5-6 ml will be needed. This may be done at anytime, including before, during, or after treatment. This is not required to participate in the study.
Study NCT01958684 — intervention group
Intervention type: DRUG
Intervention: Levonorgestrel IUS (Mirena, BAY86-5028)
Description: LNG-IUS once inserted will be effective for 5 years.
Study NCT01958684 — intervention group
Intervention type: DEVICE
Intervention: Copper-IUD
Description: Copper-IUD once inserted will be effective for more than 10 years.
Study NCT02090595 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MBCT-C
Description: A 12 week group therapy program for children with anxiety disorders. This involves teaching the children the pay attention to anxiety related cues with openness and non-judgment. Group leaders begin each session with: sitting meditation, review of the previous session and home practices, teaching a new mindfulness exercise, reading a group poem or story, distributing handouts, etc. There will be a new theme each week.
Study NCT02090595 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Waitlist Control
Description: Waitlist Control (WC) will be the comparison condition. Some of the children in the study will initially participate in a 12 week WC prior to their participation in the MBCT-C. At each visit during the waitlist control period, participants and their families will receive materials about mood and anxiety disorders in youth, bipolar disorders, familial risk for bipolar disorder and treatment strategies for anxiety and depression in youth.
Study NCT01233830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: oral solution
Study NCT01233830 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral solution
Study NCT03096353 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: saline
Study NCT03096353 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxone
Description: We will be using naloxone at normal clinical doses as the study drug. Naloxone is an opiate antagonist and has been used since the 1960 s to reverse the effects of opiate overdoses.
Study NCT02748993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 Cream 0.1%
Description: Topical application
Study NCT02748993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 Cream 0.3%
Description: Topical application
Study NCT02748993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PAC-14028 Cream 1.0%
Description: Topical application
Study NCT02748993 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: PAC-14028 Cream Vehicle
Description: Topical application
Study NCT03617432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: Chidamide 15mg orally BIW. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study NCT00618150 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient education
Description: An educational program: Three lessons spaced over 2 weeks.
Study NCT01802359 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an observational study. Korean male participants receiving mirodenafil as per the prescribing information will be observed.
Study NCT04290182 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MSC-KI-PL-204
Description: Autologous MSC product
Study NCT00701987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALS-357
Description: Topical application of ALS-357
Study NCT02133417 — intervention group
Intervention type: DEVICE
Intervention: Quantitative Transmission Ultrasound
Description: Quantitative Transmission Ultrasound (QTUS) as an automated breast ultrasound procedure for women who have a mammographically detected mass.
Study NCT01964248 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo cream applied 2 hours before blood sample
Study NCT01964248 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lidocaïne/prilocaïne 5%
Description: Application cream lidocaïne/prilocaïne (5%) 2 hours before blood sample
Study NCT02547623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: depot intracameral
Study NCT02547623 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone
Description: Prednisolone eye drops 1%
Study NCT03728049 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: CT-ADP performed during TAVI procedure
Description: The CT-ADP will be performed in the catheterization laboratory and revealed to the operator. The decision to undertake corrective procedure will be based on CT-ADP on top of standard methods of PVR assessment.
Study NCT03728049 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No CT-ADP performed during TAVI procedure
Description: PVR assessment with the standard methods only (TTE and/or angiography and/or hemodynamics but excluding TEE and CT-ADP). The decision to undertake corrective procedure will be left at the discretion of the operator.
Study NCT05196893 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Link Intervention
Description: Eligible students met with staff trained in specialize intervention skills. Staff met with students multiple times per month, for approximately 10-30 minutes. During these sessions, staff had conversations with students, using intervention communication skills, assessed student stress, and implemented strategies for behavior change. Details of the sessions were recorded in a case management tool. Students were referred to additional resources, as necessary, and these referrals were also recorded. Rates of student office referrals were assessed over time.
Study NCT01795651 — intervention group
Intervention type: PROCEDURE
Intervention: identification of take-home message of lecture
Study NCT00826514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tanezumab
Description: Intravenous, 20 mg, single dose.
Study NCT03617432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide(750mg/m2) was administered intravenously on d1. Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study NCT00826514 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous placebo, single dose
Study NCT03617432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin (50mg/m2)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study NCT03617432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine (1.4mg)was administered intravenously on d1.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study NCT03617432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide (100mg/m2) was administered intravenously on d1,2,3.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study NCT03617432 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (100mg)was administered by oral on d1-5.Six cycles of therapy will be administered, and each cycle of treatment is 21 days.
Study NCT01219621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Symphony Dual Chamber Rate Responsive Device
Description: Echocardiography ANP/BNP measurements
Study NCT00984945 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5 VLP pandemic influenza vaccine 5 µg
Description: 0.5 mL, IM, 2 injections 21 days apart
Study NCT00984945 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5 VLP pandemic influenza vaccine 10 µg
Description: 0.5 mL, IM, 2 injections 21 days apart
Study NCT03678974 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise Prescription
Description: The CardioCoach Vo2Max app allows the physician to upload an individual's Vo2 Max and resting metabolic rate results to the app which will allow each subject to view those results in the context of workout zones, goals, and energy balance. The app shows time spent aerobic versus anaerobic, and the actual number of calories burned during a workout and post-workout. It will also show what fuel source (Fats vs Carbs) are being used in real time during your workouts. Subjects can be guided through their workouts utilizing voice coaching to keep you in your customized zones. Additionally, the app accommodates a quick add of calories directly to the app to track calories consumed vs calories burned.
Study NCT00749606 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual telephone intervention
Description: Individually administered telephone-based weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff.
Study NCT00749606 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group telephone intervention
Description: Group education conference calls administered weight loss intervention based on the Diabetes Prevention Program (weekly nurse calls for the first 5 weeks, then monthly, to cover the 16 topics from the Diabetes Prevention Program). In year 1 (after the first 5 weeks), the coach will have 3 weekly calls per month with participants. Contact will decrease to monthly in year 2. In year 3 there will be no contact arranged by study staff.
Study NCT01219621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Symphony Dual Chamber Rate Responsive Device
Description: Echocardiography ANP/BNP measurements
Study NCT00984945 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: H5 VLP pandemic influenza vaccine 20 µg
Description: 0.5 mL, IM, two injections 21 days apart
Study NCT00984945 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 0.5 mL, IM, two injections 21 days apart
Study NCT04148729 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Control Group
Description: In this group Ultrasound guided ESP block will not perform. Postoperative analgesia will provide with 0.1 microgram morphine (IV) and diclofenac sodium 75 mg intramuscularly.
Study NCT03869268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspirin
Description: Aspirin will be allocated in different doses and will be used in conjunction with ticagrelor depending on the arm of the trial the participant is randomised to. The different doses are as follows: 20 mg, 75 mg and 300 mg.
Study NCT03869268 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ticagrelor
Description: Ticagrelor will be allocated as a single loading dose of 180 mg (2 x 90 mg orodispersible tablets) and will be used in conjunction with aspirin depending on the arm of the trial the participant is randomised to.
Study NCT04247048 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: infusion of tracer [5,5,5-2H3] -L-leucine
Description: A bolus of 6ml of \[5,5,5-2H3\] -L-leucine tracers will be performed followed by an infusion of 90 ml of \[5,5,5-2H3\] -L-leucine infused over 14 hours. This tracer participates in protein synthesis and especially in the synthesis of all apolipoproteins and PCSK9. Blood samples will be taken at T0, T2min, T5min, T10 minutes, T30 minutes and then every hour until 14 hours (a total of 240 ml of blood will be collected) to measure the stable tracer enrichment in the proteins of interest.
Study NCT03681717 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Participants wear a Virtual Reality headset that consists of a ASUS phone and a ReTrack Utopia 360 VR Headset. The phone runs the VR Roller Coaster app to produce the virtual environment.
Study NCT01577862 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colistin
Description: 2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days
Study NCT01577862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Colistin
Description: 2 million units every 8 hours intravenously for at least 10 and up to a maximum of 21 days
Study NCT01577862 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifampicin
Description: 600 mg every 12 hours intravenously
Study NCT03756090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Palbociclib
Description: Palbociclib will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
Study NCT03756090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule will be administered orally as 125mg capsules, daily on a schedule of 3 weeks (21 days) on, 1 week (7 days) off of a 4 week \[28 days\] cycle.
Study NCT03756090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Epirubicin
Description: Epirubicin (90mg/m2, D1) cycled every 14 days for the first 4 cycles.
Study NCT03756090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin
Description: Epirubicin (90mg/m2, D1) cycled every 14 days for the first 4 cycles.
Study NCT03756090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Cyclophosphamide
Description: Cyclophosphamide (600mg/m2, D1) cycled every 14 days for the first 4 cycles.
Study NCT03756090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (600mg/m2, D1) cycled every 14 days for the first 4 cycles.
Study NCT03756090 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Paclitaxel
Description: Paclitaxel (80mg/m2, D1) cycled every 14 days for the later 4 cycles.
Study NCT03756090 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel (80mg/m2, D1) cycled every 14 days for the later 4 cycles.
Study NCT03931655 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Spectroscopic photoacoustic imaging
Description: Spectroscopic photoacoustic imaging uses a laser that is pulsed for a nanosecond, applying laser light to the patient's skin. Hemoglobin and melanin absorb the laser's energy and convert it to heat, which rapidly expands local tissue and produces a broadband ultrasound wave and is detected with a clinical ultrasound transducer. Because the signal is proportional to the optical absorption in tissue, high resolution images of the lymph nodes can be acquired from the detected ultrasound waves, and can be used to measure saturated oxygen in the nodes.
Study NCT03964571 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: WOUNDCHEK
Description: fluid swab of wound and measurement of wound onto film
Study NCT02257255 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pfannenstiel cesarean section
Description: Pain scales ( VAS and McGill ) 6, 12 and 24 hours after cesarean to pain assessment
Study NCT02257255 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Misgav-Ladach cesarean section
Description: Pain scales (VAS and McGill) 6, 12 and 24 hours ater cesarean to pain assessment
Study NCT02384005 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Self-anal exam arm
Description: After a short pre-test the clinician will use a model to show a normal and diseased anal canal and then use pictures to show a self-DAE. The clinician will describe how to do a self-DAE for single men and partners. Next, the clinician will ask the participant to lower his pants for collection of anal human papillomavirus (HPV) DNA and cytology. The clinician will conduct a DAE and then participants will do self-DAE done in private. Then the research assistant will demonstrate the computer-assisted self-interview. When participants return to the clinician to receive the DAE results, the clinician will conduct a safety-related interview. The clinician will treat external anal disease, triage internal anal disease, and ask to be notified if a participant has any anus-related concerns in the following week. A complete appointment will require 70 minutes for singles and 105 minutes for couples. The PI will later conduct 3 focus groups.
Study NCT02865057 — intervention group
Intervention type: PROCEDURE
Intervention: Vaginal assessment
Description: Vaginal assessment of position prior to delivery
Study NCT00283387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Betaine
Description: Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
Study NCT04608188 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Summer Camp
Description: The intervention camps will operate according to routine practice, with no assistance from the investigative team. The camps provide indoor and outdoor opportunities for children to be physically active each day, provide enrichment and academic programming, as well as provide breakfast, lunch, and snacks. All camp meals will adhere to the United States Department of Agriculture Summer Food Service Program nutrition guidelines. The camps employ 1 staff member for every 12 children - which is consistent with childcare regulations in the state of operation and operate daily (Mon-Fri) for 8 weeks during the summer. The camps open at 7am and close 6 pm daily.
Study NCT00055237 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg day intravenously on day 1, day 8, then every 3 weeks.
Study NCT04355273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: heparin with a concentration of 2 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
Study NCT04355273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Heparin
Description: heparin with a concentration of 4 U/ml is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
Study NCT00283387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Betaine
Description: Subjects were randomly assigned oral betaine 12 grams/day in subjects younger than 10 years of age, and 20 grams/day in subjects 10 years of age and older, in two divided doses, for 2 months.
Study NCT00283387 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Subjects received oral lactose placebo, in two doses daily, for 2 months.
Study NCT04567082 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Examination of saliva
Description: Collection of saliva samples
Study NCT00030186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CEP-701 60mg
Description: 60mg orally 2 times a day for 28 days
Study NCT00030186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cep-701 80mg
Description: 80mg 2 times a day, dependent upon response to cycle 1
Study NCT00030186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cep-701 40mg
Description: 40mg 2 times a day, dependent upon response to cycle 1
Study NCT00283387 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects received oral lactose placebo, in two doses daily, for 2 months.